Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.47 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.47 |
| ▸ | GLP1R | P43220 | 2/20 | 0.46 |
| ▸ | CALCR | P30988 | 4/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654742 | 0.86 | BACE1 (0.59) | BACE1VIPR2VIPR1CTSD | |
| SCHEMBL30240002 | 0.85 | ENPEP (0.43) | BACE1F2VIPR2VIPR1GLP1R | |
| SCHEMBL31147166 | 0.85 | F2 (0.48) | F2CTSD | |
| SCHEMBL9751592 | 0.84 | OPRK1 (0.45) | BACE1CTSD | |
| SCHEMBL9751589 | 0.84 | OPRK1 (0.45) | BACE1CTSD | |
| SCHEMBL31182644 | 0.84 | CALCR (0.54) | BACE1CRHR1CRHR2VIPR2VIPR1 | |
| SCHEMBL30209777 | 0.84 | GLP1R (0.50) | BACE1F2CRHR1CRHR2GLP1R | |
| SCHEMBL31147163 | 0.83 | F2 (0.47) | F2CTSD | |
| SCHEMBL30293834 | 0.83 | NTSR2 (0.45) | BACE1F2 | |
| SCHEMBL31574018 | 0.83 | BACE1 (0.44) | BACE1CRHR1CRHR2VIPR2VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852453-A | Incretin analogue, preparation method and application thereof | 上海多米瑞生物技术有限公司 | 2024-10-29 | — | — | CN | disclosed |